CRA assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. CRA’s evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
The Media Show - Reporting on the Abuse of Power
Philip Marsden discusses some of the ramifications of the UK Government’s approach to Digital Regulation, ahead of the Queen’s Speech this week. For more...